araag2/HINT huggingface dataset:
Clinical trial NCT01128894 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: liraglutide
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of type 2 diabetes mellitus and experiencing inadequate glycemic control on
             their current regimen of metformin, TZD, SU, or any combination of these oral
             antidiabetic medications

          -  BMI >/=20kg/m2 and </=45 kg/m2

          -  Fasting C-peptide >/=0.8 ng/mL (>/=0.26 nmol/L)

          -  HbA1c between 7.0% and 10.0%, inclusive

          -  Female subjects of childbearing potential must be practicing adequate contraception.

        Exclusion Criteria:

          -  History of cancer

          -  History of treated diabetic gastroparesis

          -  Current biliary disease or history of pancreatitis

          -  History of significant GI surgery

          -  Recent clinically significant cardiovascular and/or cerebrovascular disease

          -  Hypertension

          -  History of human immunodeficiency virus infection

          -  History of or current liver disease or acute symptomatic infection with hepatitis B or
             hepatitis C

          -  History of alcohol or substance abuse

          -  Female subject is pregnant, lactating, or <6 weeks postpartum

          -  Known allergy to any GLP 1 analogue, liraglutide, other study medications' excipients,
             excipients of albiglutide, or Baker's yeast

          -  History of type 1 diabetes mellitus

          -  Contraindications (as per the prescribing information) for the use of either
             background or potential randomized study medications (e.g., liraglutide)

          -  Receipt of any investigational drug or liraglutide within the 30 days or 5 half lives,
             whichever is longer, before Screening or a history of receipt of an investigational
             antidiabetic drug within the 3 months before randomization or receipt of albiglutide
             in previous studies

          -  History or family history of thyroid disease
Clinical trial NCT00221702 (phase 3, status: completed)
Conditions: melanoma, neoplasm metastasis
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: pegintron, intron a
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven cutaneous melanoma

          -  Tumour thickness >= 1.5 mm (Breslow staging)

          -  Absence of clinically detectable regional node metastasis, no evidence of distant
             metastasis

          -  Informed consent form signed

        Exclusion Criteria:

          -  Any prior chemo-, immuno-, hormonal or radiation therapy

          -  Macroscopic disease
Clinical trial NCT00494299 (phase 3, status: completed)
Conditions: carcinoma, hepatocellular
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: sorafenib (nexavar, bay43-9006), placebo
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female

          -  Aged of 18 and over

          -  Advanced hepatocellular carcinoma

        Exclusion Criteria:

          -  History of prior systemic chemotherapy

          -  Failure in vital organ
Clinical trial NCT01542788 (phase 3, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: sof, rbv, placebo to match sof, placebo to match rbv
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Infection with HCV genotype 2 or 3

          -  Cirrhosis determination

          -  Subject meets one of the following classifications:

               1. IFN unwilling

               2. IFN ineligible

               3. IFN intolerant

          -  Screening laboratory values within defined thresholds

          -  Subject has not been treated with any investigational drug or device within 30 days of
             the Screening visit

          -  Use of highly effective contraception methods if female of childbearing potential or
             sexually active male

        Exclusion Criteria:

          -  Prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein
             (NS)5B polymerase

          -  Pregnant or nursing female or male with pregnant female partner

          -  Current or prior history of clinical hepatic decompensation

          -  History of clinically-significant illness or any other major medical disorder that may
             interfere with subject treatment, assessment or compliance with the protocol

          -  Excessive alcohol ingestion or significant drug abuse
Clinical trial NCT01220596 (phase 3, status: unknown status)
Conditions: hepatitis b, chronic
ICD codes: B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: entecavir and pegylated interferon α-2a sequential treatment group, pegylated interferon α-2a monotreatment group
SMILES: NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic hepatitis B patients with HBeAg positive, HBsAg positive, HBV DNA > 100,000
             copies/ml and anti-HBs negative, serum ALT exceeding 2 X ULN but less than 10 X ULN.

        Exclusion Criteria:

          -  Patient infected concurrently with HCV, HDV and HIV or patient with a history of
             antiviral treatment for Hepatitis B or patient with hepatic decompensation.
Clinical trial NCT00727987 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: cnto 148, placebo, methotrexate (mtx)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients diagnosed with rheumatoid arthritis at least 3 months prior to registration
             and who are definitely identified as having rheumatoid arthritis, at the time of
             informed consent, according to the criteria for classification established by the
             American College of Rheumatology (1987)

          -  Patients in whom MTX therapy (>= 6 mg/week) was started more than 3 months before the
             first administration and who have been treated with MTX at a stable dose (6-8 mg/week)
             for at least 4 weeks before the first administration

          -  Patients having at least 4 swollen joints and at least 4 tender joints at the time of
             registration and immediately before the first administration.

        Exclusion Criteria:

          -  Patients with a history of hypersensitivity to human immunoglobulin proteins or other
             ingredients of golimumab

          -  Patients who have previously experienced or are suffering from any of the following
             diseases: (i) Collagen diseases other than rheumatoid arthritis, (ii) Latent or active
             granulomatous infections such as histoplasmosis and coccidioidomycosis, (iii) Felty
             syndrome, etc

          -  Patients with a severe, advanced, or poorly controlled disease in any of the kidney,
             liver, blood, gastrointestinal system, endocrine system, lung, heart, nervous system,
             psychiatric system, and brain.
Clinical trial NCT00447603 (phase 3, status: terminated)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: hydrochlorothiazide (+) losartan potassium, losartan potassium, placebo for losartan, placebo for losartan/hctz
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1, CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    achieving site readiness and enrolling the trial within a reasonable time
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is male/female and 6 to 17 years of age at the time of study with hypertension
             (high blood pressure)

          -  Patient is able to swallow tablets

          -  Females of child bearing potential must use acceptable contraception throughout the
             trial

        Exclusion Criteria:

          -  Patient has a history of heart, metabolic or kidney disease

          -  Patient has a history of known heart, lung, liver and other body system disorders

          -  Patient is pregnant or nursing

          -  Patient has participated in another clinical trial within the last 28 days
Clinical trial NCT00005834 (phase 3, status: terminated)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: cisplatin, cyclophosphamide, dexamethasone, etoposide, thalidomide
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically or cytologically confirmed stage I, II, or III
        multiple myeloma with protein criteria present Quantifiable M-components of IgG, IgA, IgD,
        IgE AND/OR Urinary kappa or lambda light chain excretion No IgM peaks Quantifiable
        monoclonal proteins Received at least 1, but no more than 4 prior treatment regimens,
        including the following: Chemotherapy Bone marrow transplantation Biologic therapy
        Radiotherapy Interferon therapy or steroid pulsing given as maintenance therapy after
        transplantation or chemotherapy is not considered a separate treatment regimen Progressive
        disease

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 (3-4 allowed if
        due solely to bone pain) Life expectancy: At least 3 months Hematopoietic: Absolute
        granulocyte count at least 1,000/mm3 Platelet count at least 50,000/mm3 (at least 50%
        plasma cells in bone marrow) Hepatic: Bilirubin no greater than 2.5 times upper limit of
        normal (ULN) SGOT or SGPT no greater than 2.5 times ULN Renal: Creatinine no greater than
        2.0 mg/dL OR Creatinine clearance at least 60 mL/min Other: Not pregnant or nursing
        Negative pregnancy test Fertile patients must use 2 methods of effective contraception for
        4 weeks before, during, and for 4 weeks after study No other prior or concurrent
        malignancies within the past 5 years except adequately treated basal cell or squamous cell
        skin cancer, carcinoma in situ of the cervix, or any other adequately treated stage I or II
        cancer in complete remission No grade 2 or greater preexisting peripheral neuropathy

        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Prior thalidomide
        allowed if received less than 3 months of therapy Recovered from prior biologic therapy
        Chemotherapy: See Disease Characteristics At least 3 weeks since prior chemotherapy and
        recovered No other concurrent chemotherapy Endocrine therapy: See Disease Characteristics
        No concurrent hormonal therapy Radiotherapy: See Disease Characteristics At least 3 weeks
        since prior extensive or limited radiotherapy and recovered No concurrent radiotherapy
        Surgery: Not specified
Clinical trial NCT00654069 (phase 3, status: completed)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: placebo, acurox 5/30 mg, acurox 7.5/30
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OC(=O)C1=CN=CC=C1, OC(=O)C1=CN=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is male or female at least 18 years of age

          -  For women of child-bearing potential: woman who is not pregnant and not nursing, and
             who is practicing an acceptable method of birth control

          -  Patient is scheduled to have a bunionectomy

          -  Patient must be willing to stay at the study site for at least 48 hours from the
             initial dose of study medication post-surgery

        Exclusion Criteria:

          -  Patient has a current disease or history of a disease that will impact the study or
             the patient's well-being

          -  Patient has used or intends to use any of the medications that are prohibited by the
             protocol

          -  Patient has a history of drug or alcohol abuse or dependence, or patient has a
             positive urine drug screen

          -  Patient is hypersensitive to any of the medications to be used in the study

          -  Patient has taken another investigational drug within 30 days prior to Screening
Clinical trial NCT01058668 (phase 3, status: completed)
Conditions: mania, bipolar i disorder
ICD codes: F31.70, F31.71, F31.72, F31.73, F31.74, F31.75, F31.76
Drugs: cariprazine, placebo
SMILES: CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have provided informed consent prior to any study specific procedures

          -  Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders,
             Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder, as
             confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual
             of Mental Disorders, Fourth Edition (SCID) manic or mixed type with or without
             psychotic symptoms

          -  Voluntarily hospitalized for current manic episode

          -  Patients with normal physical examination, laboratory, vital signs,and/ or
             electrocardiogram (ECG)

        Exclusion Criteria:

          -  Patients with a DSM-IV-TR diagnosis of an axis I disorder other than bipolar I
             disorder that was the primary focus of treatment within the previous six months
Clinical trial NCT00095823 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: antidepressant + placebo, antidepressant + aripiprazole
SMILES: FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1, ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women, 18-65 years old

          -  Experienced a Major Depressive Disorder with the current episode of minimally 8 weeks
             in duration.

          -  Treatment history of an inadequate response to at least one and no more than three
             antidepressants.
Clinical trial NCT00150306 (phase 3, status: terminated)
Conditions: stress disorders, post-traumatic
ICD codes: F43.10, F43.11, F43.12
Drugs: zoloft (sertraline)
SMILES: CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
Reason stopped: 
    please see detailed description below for termination reason.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must be from 6 to 17 years of age and will have a maximum age of 17 at the
             Baseline Visit of the study.

          -  Subjects must have a diagnosis of Posttraumatic Stress Disorder as defined by DSM-IV
             and determined by the Kiddie Schedule for Affective Disorders and Schizophrenia for
             School-Age Children-Present and Lifetime Version (K-SADS-PL).

        Exclusion Criteria:

          -  Subjects whose trauma is ongoing, or who are living in the same home as their abuser,
             or who are expected to participate in litigation related to their trauma during the
             course of the study will be excluded from participation.

          -  Subjects who are likely to or are at high risk for experiencing re-exposure to their
             index trauma.
Clinical trial NCT01272219 (phase 3, status: completed)
Conditions: metabolism and nutrition disorder, obesity
ICD codes: E70.5, E71.32, E72.4, E76.9, E78.89, E83.2, E88.40, E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: liraglutide, placebo, liraglutide, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent obtained

          -  Body Mass Index (BMI) of 30.0 kg/m^2 or above

          -  Body Mass Index (BMI) of 27 kg/m^2 or above in the presence of co-morbidities of
             treated or untreated dyslipidemia and/or hypertension

          -  Stable body weight

          -  Preceding failed dietary effort

        Exclusion Criteria:

          -  Known type 1 or type 2 diabetes

          -  Glycosylated haemoglobin (HbA1c) of 6.5 % or above (Screening visit 1) or FPG of 126
             mg/dL (7 mmol/L) or above (Screening visit 2) or 2 hour post-challenge (OGTT) plasma
             glucose of 200 mg/dL (11.1 mmol/L) or above (Screening visit 2)

          -  Screening calcitonin of 50 ng/L or above

          -  Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial
             medullary thyroid carcinoma (FMTC)

          -  Personal history of non-familial medullary thyroid carcinoma

          -  History of acute or chronic pancreatitis

          -  Obesity induced by drug treatment

          -  Use of approved weight lowering pharmacotherapy

          -  Previous surgical treatment of obesity

          -  History of major depressive disorder or suicide attempt

          -  Uncontrolled hypertension (systolic blood pressure of 160 mmHg or above and/or
             diastolic blood pressure of 100 mmHg or above)
Clinical trial NCT00508222 (phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: kaletra tablets
SMILES: CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria

          1. Subject has confirmed his or her willingness to participate in the study after being
             informed of all aspects of the trial that are relevant to his or her decision to
             participate, by signing and dating the IRB / IEC approved informed consent form.

          2. Subject is both HIV positive and HCV positive (must be viremic for HCV, not just
             antibody positive).

          3. Subject is 18 years of age or older.

          4. Subject must have an undetectable viral load (VL) less than 50 copies/ml for the last
             6 months on HAART therapy.

          5. Subject must not be taking any medication that could interact with Kaletra® to enhance
             hepatic toxicity.

          6. Subject's serum AST and ALT levels must be &lt;5 times normal (grade 2 or less) at the
             start of the study.

          7. Subject must not harbour viral strains that are resistant to Kaletra® at the start of
             the study.

          8. Subject has a Karnofsky Score 70 or greater.

          9. If female, subject must have a negative pregnancy test and agree to use, for the
             duration of the study, a barrier method of birth control that has a history of proven
             reliability as judged by the investigator.

         10. Subject does not require and agrees not to take, for the duration of the study, any
             medication that is contraindicated with Kaletra® (list will be in the protocol).

        Exclusion Criteria

          1. Subject has active hepatitis B (HbsAg +).

          2. Subject has a history of substance abuse or psychiatric illness that could preclude
             compliance with the protocol.

          3. Subject has any of the following abnormal laboratory test results at screening:

               -  Hemoglobin 8.0 g/dL or more

               -  Absolute neutrophil count 500 cells/mL or more

               -  Platelet count 20,000/mL or more

               -  ALT or AST 5x Upper Limit of Normal (ULN) or more

               -  Creatinine 1.5 x ULN or more

          4. Female subject is pregnant or lactating.

          5. Subject has received an investigational drug within 30 days prior to the initiation of
             study dosing.

          6. Subject exhibits viral strains that are resistant to lopinavir.

          7. Subject is receiving systemic chemotherapy.

          8. The subject, in the opinion of the principal investigator, is unlikely to comply with
             the study protocol or is unsuitable for any other reason.
Clinical trial NCT00560404 (phase 3, status: completed)
Conditions: anemia
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: methoxy polyethylene glycol-epoetin beta [mircera], epoetin alfa
SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  chronic renal anemia;

          -  regular hemodialysis with the same schedule of dialysis for >=12 weeks;

          -  maintenance therapy with subcutaneous epoetin alfa at the same administration interval
             for 4 weeks.

        Exclusion Criteria:

          -  transfusion of red blood cells during previous 2 months;

          -  poorly controlled hypertension requiring interruption of epoetin alfa in previous 6
             months;

          -  acute or chronic bleeding;

          -  active malignant disease (except non-melanoma skin cancer).
Clinical trial NCT00640263 (phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: lopinavir/ritonavir (lpv/r), lamivudine (3tc)
SMILES: CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1
Eligibility criteria:

        Inclusion Criteria: A baby will be included if she/he:

          -  is a singleton

          -  is breastfed at day 7 by her/his mother and her/his mother intends to continue
             breastfeeding for at least 6 months

          -  has a post-partum blood sample with a negative HIV-1 DNA PCR test result at day 7 (+/-
             2 days)

          -  has received ART as part of PMTCT

        and if the mother:

          -  has reached the local legal age for participating in medical research studies

          -  is shown to be HIV-1 infected (with or without HIV-2 infection) and is not eligible
             for HAART or is not taking HAART

          -  has received a perinatal antiretroviral prophylaxis during pregnancy and delivery,

          -  has a CD4 count above the threshold of HAART initiation in pregnant women according to
             the national recommendation in each site (minimum 230 cells/µL),

          -  resides within the study area and is not intending to move out of the area in the next
             year

          -  gives assent for the infant to participate and gives consent to participate

        Exclusion Criteria:

          -  S/he presents clinical symptoms and/or biological abnormalities equal to or greater
             than grade II of the ANRS classification for adverse event on the day of enrolment

          -  S/he presents with serious congenital malformation(s)

          -  Her/his birth weight is lower than 2.0 kg

          -  Her/his antiretroviral prophylaxis is extending beyond day 7

          -  The mother has participated in the trial for a previous pregnancy

          -  S/he and her/his mother are participating in another clinical trial on the day of
             enrolment